Therapy Areas: Inflammatory Diseases
Shattuck Labs Initiates Phase 1 Clinical Trial of SL-279252
9 May 2019 - - Patients are being treated in US-based biopharmaceutical company Shattuck Labs, Inc.'s Phase 1 dose escalation and expansion clinical trial of its molecule SL-279252 (PD1/OX40L), a bi-functional fusion protein, the company said.

Sarah Cannon Research Institute in Nashville, Tennessee and MD Anderson Cancer Center in Houston, Texas are the first enrolling sites in this multi-center, global trial.

This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and anti-tumor activity of SL-279252 in patients with advanced solid tumors or lymphomas.

Takeda Pharmaceutical Company currently holds an exclusive option to enter into a license to develop and commercialize SL-279252.

SL-279252 is a novel therapeutic derived from Shattuck's proprietary Agonist Redirected Checkpoint platform and its first molecule to begin clinical trials.

The dual-sided nature of SL-279252 is designed to simultaneously block the PD-L1 inhibitory signal and stimulate OX40 signaling.

Preclinical studies have demonstrated that SL-279252 potently stimulates anti-tumor T cell activity.

Shattuck is a clinical-stage biopharmaceutical company developing its Agonist Redirected Checkpoint platform, a novel class of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases.

Using its proprietary ARC platform, Shattuck is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. Shattuck has offices in Austin, Texas and Durham, North Carolina.
Login
Username:

Password: